

IMMUNE SAFETY AVATAR

Nonclinical mimicking of the immune system effects of immunomodulatory therapies

Deliverable 1.4 <u>2nd imSAVAR</u> Workshop

DELIVERABLE REPORT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.











Abstract

The imSAVAR second stakeholder workshop was held on the fourth of November 2020. There were 51 attendees. The focus was on the Checkpoint Inhibitor Mechanism of action. The workshop began with a presentation of the work that has been done to complete a immune related adverse outcome pathway for checkpoint inhibitors.

A major outcome of the discussion was that while the original concept was that for each MoA there would be one irAOP, for checkpoint inhibitors this concept is not useful as there are multiple different types of checkpoint inhibitors with different type of toxicities and in different organ systems.

The regulatory perspective provided by one of the regulatory experts from the partner was that indeed there should be specific irAOPS. She also pointed out that there are not a lot of organ on the chip systems in the current dossiers meaning this may be something that could be a topic more formal regulatory advice.

The plan is to move forward with the different irAOPS with the development of more case studies, engagement of industry partners and evolution of the organ on a chip models.



Document Information

Deliverable Report	D1.4: 2 nd imSAVAR Workshop
Date	15.01.2021
Report prepared by	Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V BioSci Consulting BVBA
Project	imSAVAR - Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies Grant Agreement No.: 853988 (IMI2-2018-15-04)
Project Coordinator	Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V. Prof. Dr. Dr. Ulrike Köhl Novartis Pharma AG Dr. Jonathan Moggs
Туре	Deliverable Report Public

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.











Table of Contents

Abst	tract	2
Age	nda 2 nd Workshop	5
1.	Presentation on Check point inhibitor irAOP	5
2.	Partner perspectives on the CPI irAOP	7
3.	In Vitro Systems towards a personalised Medicine approach	9
4.	What do we do and what can we do? 1	.3
5.	Should you have a single irAOP for each case study or multiple irAOPs for each case study?1	.6
6.	Is the irAOP the right approach? 1	.6
7.	Regulatory perspective 1	.7
8.	Organ on chip models1	.7
9.	Who is most interested in this MoA? 1	.8
10.	Plan for moving forward 1	.8
Ackı	nowledgement 2	20



2.

Agenda 2nd Workshop

- 1. irAOP and case studies Covance 20 minutes
 - What do we do and what can we do Novartis 10 minutes
- 3. Discussion
 - a. Who is most interested in this MoA?
 - b. irAOP the right approach?
 - c. Target organ specificity which organs are the most important?
 - d. Modelling autoimmune-like toxicity
- 4. Regulatory perspective
- i. Ex. Does it make sense to do a CRS assay for this MoA?
 - a. Biosimilar development
 - b. Access to test molecules
 - c. Awareness of other initiatives in the field
 - d. Focus and plan
- j. Models to work on etc.

1. Presentation on Check point inhibitor irAOP

Developed based on IL-6 and Cytokine Release Syndrome because of what was found in the literature and the fact that patients respond to anti-IL6. Feedback from the consortium:


- consider combinations
- include AOPs other that CRS
- contribution of auto-antibodies
- Expand mode of action scope

Impact


• qualify/disqualify the utiliity of the novel models/biomarkers




irAOP for ICIs




irAOP for ICIs - include ICIs combinations











2. Partner perspectives on the CPI irAOP


Contributions of COVANCE to imSAVAR:








Anti-PD-1 case study








3. In Vitro Systems towards a personalised Medicine approach

Contributions of Transgene to imSAVAR:



Oncolytic Virus (OVs) & ICI : MOA



Oncolytics Vaccinia Virus (oVV) & ICI

Combination :

PDL-1: Liu, Z., Ravindranathan, R., Kalinski, P. et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 8, 14754 (2017).

CTLA-4: Rojas, Juan J et al. "Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy." Clinical cancer Research vol. 21,24 (2015): 5543-51.

CTLA-4 & PDL-1 : Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki, Midori Yamashita, Ryuji Murakami, Tatsuya Kawase, Nobuaki Amino, Motomu Nakatake, Hajime Kurosaki, Masamichi Mori, Masahiro Takeuchi and Takafumi Nakamura. Science Translational Medicine 15 Jan 2020:Vol. 12, Issue 526.

CTLA-4 & PD-1: Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Préville X, Quéméneur E, Kepp O, Adam J, Marabelle A, Pitt JM, Kroemer G, Zitvogel L. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Res. 2017 Aug 1;77(15):4146-4157.

Armed :

CTLA-4: BT-001, an oncolytic vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment (and combination with PD-1)

Jean-Baptiste Marchand, Monika Semmrich, Laetitia Fend, Matilda Rehn, Nathalie Silvestre, Ingrid Teige, Johann Foloppe, Linda Mårtensson, Eric Quéméneur and Björn Frendeus. Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA

PD-1: Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition Kleinpeter, Patricia & Fend, Laetitia & Thioudellet, Christine & Geist, Michel & Sfrontato, Nathalie & Koerper, Véronique & Fahrner, Catherine & Schmitt, Doris & Gantzer, Murielle & Remy-Ziller, Christelle & Brandely, Renée & Villeval, Dominique & Rittner, Karola & Silvestre, Nathalie & Erbs, Philippe & Zitvogel, Laurence & Quemeneur, Eric & Preville, Xavier & Marchand, Jean-Baptiste. (2016). Oncolmmunology. 5. 00-00. 10.1080/2162402X.2016.1220467.




10



oVV encoding anti-CTLA-4 mAb



4





oVV Virotherapy AES


Therapeutic mode of action	Models/End point	Clinical Adverse Events
Depending on OV arming	Human in vitro Models -cell lines	Flu like syndrome (fever, chills, headache,)
Cytokines: Proliferation CTL activitiy Memory cross- priming, expansion of tumor	-patient derived Models (organoïds, 3D printed): Lung, CRC	Skin lesion
specific $T_H 1$, reverse tolerance ICI: anti-tumoral activity, combinations boost effects with Ovv	PBMCs: Functional assays (MDSC + T proliferation, M2+T proliferation, NK cytolysis assay -Skin Model	Vascular disorder: Mild to moderate hypotension (Transient)
	Non-Human primates Skin lesions, viral shedding, PK of transgene product	HepatotoxAST, ALT(Rare event)
	Dog Patients Mouse models*	Heart failure (rare event)
	Syngeneic models: IFN production, cytotoxic activity, Nude Mice efficacy PDX mice efficacy	Neurotoxicity (rare event)
	*	ivitute « human » OVa

transgene

* Low permissivity to « human » OVs



oVV plus ICI combination Tox on chip



Lab Chip, 2020, 20, 446



3Rs Transgene objectives

- Making personalized organs-on-chips from tissues of specific patients in order to select best therapeutic (High Content Low Throughput):
 - MOA
 - Tox (skin, brain, heart, liver)
- Tissue-Tissue Interface (Blood vessels, Brain blood barrier)
- Human tumor and healthy tissues (Gastro-intestinal models, Lung, Skin (oVV-CTLA-4), Liver Mets)
- Endothelial cell (Vasculature Model, Lymph circuit, ...)
- Immune compartment (Synthetic LN, PBMC, ...); Immune cells trafficking in presence of tumor cells compartment



6



4. What do we do and what can we do?

Jonathan Moggs (Novartis):

- There are significant clinical toxicities in checkpoint inhibitors
 - o Hepatotoxicity
 - Cytokine Release syndrome
 - o Cardiovascular
 - Combination therapies have a synergistic toxicity
- MoA scope is very broad
- Combinations are also very broad
 - What is the best way to assess combination immune toxicities
- There are lots of clinical databases
- Drug inserts are great sources of list of toxicities seen
- Should be focused on more severe and difficult to predict toxicities that are dose limiting
- Anticipated impact
 - o Benchmark models/biomarkers in animal models
 - o Identify safe first in human start dose
 - know how to monitor in clinic
 - identify mitigation strategy
 - o Biosimilars need nonclinical models to assess that thet are not
- anti-CTL4 case study as presented by Jim Munroe
- Can't do too many toxicities or MoAs
 - Liver Toxicity looks the most promising

IMI imSAVAR consortium goals: Enhanced safety assessment of immunomodulatory therapeutics 						
 Evaluate utility of integrating non-clinical and clinical safety experience with data derived from human <i>in vitro</i> immune cellular models, "engineered" animal models, and innovative immunophenotyping endpoints First-In-Human (FIH)-enabling non-clinical safety package Improved models? Clinical safety profile 						
Initial focus on therapeutic modes of action where prediction of human toxicities is suboptimal	Models/endpoints	Clinical adverse events				
Treg modulators (e.g. rhIL-2) Immune checkpoint inhibitors (antibodies, small molecules; oncolytic viruses; combinations) Engineered T cell therapies (e.g. CART) T cell engaging antibodies (e.g. CD3 Bispecifics)	Human <i>in vitro</i> immune models (+/- patient-derived cells) Humanized animal models Enhanced pharmacodynamic and toxicodynamic biomarkers	Target organ-specif toxicities Autoimmune-like phenotypes Cytokine release syndrome & neurotoxicity				



Enhancing safety assessment for immune checkpoint inhibitors

(antibodies, small molecules, oncolytic viruses; combinations)

Initial focus on therapeutic modes of action when prediction of human toxicities is suboptimal	e Models/endpoints	Clinical adverse events
Immune checkpoint inhibitors (antibodies, small molecules; oncolytic viruses; combinations)	Human <i>in vitro</i> immune models (+/- patient-derived cells) Humanized animal models Enhanced pharmacodynamic and toxicodynamic biomarkers	Target organ-specific toxicities Autoimmune-like phenotypes Cytokine release syndrome & neurotoxicity
Immune checkpoint inhibitor combination toxicities		Hepatitis
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents	Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-	Cytokine release syndrome
Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for	oncology	Fulminant myocarditis

Translational safety assessment case studies for immune checkpoint inhibitor Ab combinations


MoA Scope:

- T cell checkpoint inhibitor antibody combinations (+ biologic or LMW immunomodulators); Oncolytic virus-mediated delivery of T cell checkpoint inhibitor antibody combinations; e.g.'s anti-CTLA-4 Ab(Ipilimumab)/vermurafenib; anti-PD-1 (Pembrolizumab)/preladenant; T-cell costimulatory receptor CD137(4-11B) agonist Abs; anti-CD73; other
- Myeloid checkpoint inhibitors (e.g. SIRPa antagonist) and combination with T cell checkpoint inhibitor Abs

Particular emphasis on combinations that are likely to result in strong (additive or synergistic) immune stimulation:

- guided by clinical safety data
- drug labels (e.g. USPIs, EPARs)
- literature
- industry partner experience
- Incidence/severity of anticipated phenotype(s)

USPI Drug Labels for Nivolumab, Atezolizumab, Keytruda indicate typical organs affected include liver, lung, kidney, skin, GI and endocrine organs. WARNEGS AND PRECATIONS
 Immune-induction promisings: Withold for moderate and persusaently vibrolic for subcriter and persusaently vibrolic for subcriter and persusaently discontinue for subcriter and subcriteria subcriteri subcriteria subcriteria subcriteria su



Skin toxicity




Translational safety assessment case studies for immune checkpoint inhibitor Ab combinations

Key areas of interest:

- Exploring the utility of humanized immune system rodent models and genetic manipulation of therapeutic targets to investigate mechanistic basis and pharmacodynamic/toxicologic biomarkers for clinical safety signals
- Exploring utility of human *in vitro* immune cell models for characterizing/predicting irAEs (in particular immune-mediated liver, heart and skin toxicity; "autoimmune-like" phenotypes)
- Benchmark imSAVAR models versus established *in vivo* rodent/non-rodent IND/FIHenabling non-clinical and clinical safety data.


Anticipated impact:

 to qualify/disqualify the utility of novel models/biomarkers for enhanced safety assessment; potential impact on setting safe FIH start dose and on clinical safety monitoring and mitigation strategies; potential impact on biosimilar comparability studies





5. Should you have a single irAOP for each case study or multiple irAOPs for each case study?



- Single irAOP vs multiple irAOPs
 - Trying to write one irAOP was difficult because there are multiple different toxicities and was hard to put into one irAOP
 - Some of the toxicities will have shared elements, but the histology of different organs are different
 - When you combine therapies it will get quite complex
- Might be best to start with the most severe and dose limiting toxicity difficult to predict then as you combine the complexity will grow
- The toxicities link well with the MPS models that are now listed in the consortium
- They would be a sort of mind map that could be used to dissect the toxicities the irAOP could be a benchmark for how to choose your models
- This will allow subteams to make the case for the individual toxicities
- In the chemical toxicity field everything starts with a molecular initiating event and often they are very similar and it is okay to use assays for the building blocks that may be used across multiple outcome pathways
- AOP is an analytical construct to explain a clinical outcome

6. Is the irAOP the right approach?

- Target organ specificity which organs are the most important? Modelling autoimmune-like toxicity - how can this be done?
 - This is a big challenge




- In the organ on a chip you do not have a model of a artificial lymph node but there \cap are macrophages and NK cells, but Alexander and Peter are working on an artificial lymph node
- It is really dependent upon the immune repetoire of the patient and this would make it very difficult to predict underlying immune response
- You could in the future you could incorporate cells from an individual patients.
- Should be three different phases
 - Healthy cell models to reflect complexity
 - Patient derived cells
 - Patient specific models 0

7. Regulatory perspective

- Ex. Does it make sense to do a CRS assay for this MoA?
- **Biosimilar development**
- Access to test molecules
- Awareness of other initiatives in the field
- Gaby has been working at PEI on monoclonal antibodies has not come across AOPs in the documentation so far. For small molecules they would have come in contact on this
 - It might be good to join the safety assessment board and the EMEA. This is 0 something we should pursue and Gaby has contacts with them.
 - They have also not seen a lot of organ on a chip models in the dossier's but there is 0 interesting in learning about these techniques

8. Organ on chip models

Liver toxicity



- cell lines (HepaRG, HUVEC, LX-2, primary macrophages) 3 freshly isolated human PBMCs. granulocytes, platelets from
- imSAVAR Deliverable Report D1.4: 2nd imSAVAR Workshop 15.01.2021

Liver-on-chip (JUH / D42)

available readouts

- cytokine release (effluent analysis)
- microscopic tissue analysis of cell markers, live cell imaging
- bile acid secretion in effluent, in situ transporter assays (in situ, imaging, effluent
- transporter efficiency assay (in situ, imaging, effluent analysis)
- flow cytometry of immune cells, typing of surface markers
- cell viability from tissue and from
- PCR, ELISA, Western Blot (cell lysis)
- metabolism (effluent analysis)
- drug metabolization on model drugs for
- modeled pathophysiological functions (established)

dothelial dysfunction (rupture of endothelial lining, loss of apica , release of soluble cell adhesion molecules)

holic fatty liver disease / non-alcoholic steatohepatitis (under de cell infiltration



- in vitro with multiple cell sources and multiple readouts
 - Can look at vasculature and hepatic chamber
 - Look at clinical readouts and any type of assay that can be performed in a 69 well plate that would allow for the testing of inhibitors
 - Could be a bridge between preclinical models and clinical outcomes
 - Has the model been tested with a positive control Rilumab
- What kind of samples would you use in the system?
 - It is easy to use the primary cells of patients into the model and iPSCs
- Can you differentiate the cells from blood?
 - So, far it has been done with iPS cell line
 - Also possible to use primary lines
 - The immune response is not so high to limit the use when it is not autologous
 - If there are protocols available to derive ipsc's from PBMCs then it would be able
- What physiological conditions are being used?
 - o Model tested for TLR agonists for inflammation and sepsis
- There are at least organ on a chip for both cardiovascular and skin
- Organ on the chip need to be benchmarked against clinical outcomes is it a better models to predict outcomes.
 - Once you establish you irAOPs and their blocks the first step would be to run the models and see if you can predict toxicities in a known case study
 - irAOPs can also be used to track progress you may also find that the sequence of key events
- Broad biomarker screening is difficult with bridging to the patient to be able to select which cytokines you have to measure in patients which fits with the work that is ongoing helps in this and how do you use that information
 - For predicting you must know the pathways in patients and linking to immunobiologstis as well

9. Who is most interested in this MoA?

- Covance
- Transgene
- Novartis
- several companies have assets that are checkpoint inhibitors. We should survey them. If it is a very few partners we have to ask if it is worth putting resource to this development.
- HESI has had working groups and public domain and most events were on the checkpoint Abs themselves. We need to make sure that we have a sense of the field at large.

10. Plan for moving forward

- 1. Survey industry and external groups for interest in MoA
- 2. Build case studies to add to the three you have
- 3. Develop toxicity specific irAOPS
- 4. Reach out to the safety committee EMEA
- 5. Bring biomarkers from WP 4 linking to clinical and other MoA's



- 6. Test models in irAOPS to predict toxicities in the case studies
- 7. Develop organ on chip models
- 8. Adjust irAOPS



Acknowledgement

The authors would like to express their gratitude to the Innovative Medicines Initiative 2 Joint Undertaking (JU) for the financial support of this research under grant agreement No 853988. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.







